Cannabis company Organigram reports Q2 loss, more than doubles revenue
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $1.44 a week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $5.77 plus GST every four weeks. After 52 weeks, price increases to the regular rate of $19.95 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 12/04/2022 (1651 days ago), so information in it may no longer be current.
MONCTON, N.B. – Cannabis company Organigram Holdings Inc. reported a loss in its latest quarter as its revenue more than doubled compared with a year ago.
The company says its net loss for the quarter ended Feb. 28 amounted to $4 million compared with a loss of $66.4 million in the same period a year earlier.
Gross revenue in what was Organigram’s second quarter totalled $43.9 million, up from $19.3 million a year earlier. Net revenue was $31.8 million, up from $14.6 million.
The company says the increase was primarily due to a rise in adult-use recreational sales and international revenue, partly offset by a lower average net selling price due to a change in product mix and a decrease in medical revenue.
In its outlook, Organigram expects its third-quarter revenue to be up from its second quarter due to ongoing sales momentum, stronger market growth and its expanded product line.
It also says it expects to benefit from greater capacity to meet demand at its Moncton campus, increased throughput at its Winnipeg facility and its acquisition of Quebec-based company Laurentian Organic Inc.
This report by The Canadian Press was first published April 12, 2022.
Companies in this story: (TSX:OGI)